Abstract
A case of severe glandular tularemia in a patient receiving anti-tumour necrosis factor (TNF) therapy is reported here. The patient required prolonged treatment with doxycycline-ciprofloxacin due to early relapse after ciprofloxacin was stopped. Tularemia may have a more severe course in patients receiving anti-TNF. This may thus be an indication for more aggressive treatment.
Keywords:
Anti-TNF therapy; Certolizumab; Psoriatic arthritis; Tularemia.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.
MeSH terms
-
Adalimumab / adverse effects*
-
Adalimumab / therapeutic use
-
Adult
-
Animals
-
Anti-Bacterial Agents / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antirheumatic Agents / adverse effects*
-
Antirheumatic Agents / therapeutic use
-
Arthritis, Psoriatic / complications
-
Arthritis, Psoriatic / drug therapy*
-
Cats
-
Certolizumab Pegol / therapeutic use
-
Ciprofloxacin / therapeutic use
-
Dogs
-
Doxycycline / therapeutic use
-
Farms
-
Female
-
France
-
Francisella tularensis / isolation & purification
-
Gentamicins / therapeutic use
-
Humans
-
Methotrexate / therapeutic use
-
Rabbits
-
Rural Population
-
Tularemia / chemically induced
-
Tularemia / diagnosis
-
Tularemia / etiology*
-
Tumor Necrosis Factor-alpha / immunology*
Substances
-
Anti-Bacterial Agents
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
Gentamicins
-
Tumor Necrosis Factor-alpha
-
Ciprofloxacin
-
Adalimumab
-
Doxycycline
-
Certolizumab Pegol
-
Methotrexate